Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 1
2005 2
2008 2
2011 2
2016 1
2020 1
2021 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for dorzolamide timolol eg
Your search for dorzolamide-timololo-eg retrieved no results
Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops.
Kim M, Jang H, Rho S. Kim M, et al. Sci Rep. 2021 Sep 9;11(1):17896. doi: 10.1038/s41598-021-97565-0. Sci Rep. 2021. PMID: 34504268 Free PMC article.
This study assessed the clinical risk factors for periorbital dermatitis (PD) after using dorzolamide/timolol eye drops in a total of 1282 glaucoma patients. ...Multivariate analyses revealed that the probability of PD increased by 8 times if they had a history of o …
This study assessed the clinical risk factors for periorbital dermatitis (PD) after using dorzolamide/timolol eye drops in a t …
Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies.
Fechtner RD, McCarroll KA, Lines CR, Adamsons IA. Fechtner RD, et al. J Ocul Pharmacol Ther. 2005 Jun;21(3):242-9. doi: 10.1089/jop.2005.21.242. J Ocul Pharmacol Ther. 2005. PMID: 15969642 Clinical Trial.
Patients with a baseline IOP > or = 24 mm Hg were randomized to either the 2% dorzolamide/0.5% timolol combination eye drops twice daily (n = 273) or 0.005% latanoprost eye drops once daily (n = 271). ...By the measures used in this analysis, the dorzolamide …
Patients with a baseline IOP > or = 24 mm Hg were randomized to either the 2% dorzolamide/0.5% timolol combination eye drop …
Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices.
Pajic B; Conductors of the Swiss COSOPT Survey (CSCS). Pajic B, et al. Curr Med Res Opin. 2003;19(2):95-101. doi: 10.1185/030079902125001434. Curr Med Res Opin. 2003. PMID: 12740152
PURPOSE: In managing glaucoma through the lowering of intraocular pressure (IOP), beta-blockers (e.g. timolol) are commonly the drug of first choice, with other drugs added to control IOP such as carbonic anhydrase inhibitors (e.g. dorzolamide). The present survey w …
PURPOSE: In managing glaucoma through the lowering of intraocular pressure (IOP), beta-blockers (e.g. timolol) are commonly the drug …
[Comparative study of the pressure lowering efficacy and variations in the ocular pulse amplitude between fixed combinations of dorzolamide/timolol and brinzolamide/timolol].
Sánchez-Pulgarín M, Martínez-de-la-Casa JM, García-Feijoó J, Sáenz-Francés F, Santos-Bueso E, Herrero-Vanrell R, García Sánchez J. Sánchez-Pulgarín M, et al. Arch Soc Esp Oftalmol. 2011 May;86(5):149-53. doi: 10.1016/j.oftal.2011.01.006. Epub 2011 Apr 16. Arch Soc Esp Oftalmol. 2011. PMID: 21624655 Clinical Trial. Spanish.
OBJECTIVE: To determine possible differences in the intraocular pressure (IOP) and ocular pulse amplitude (OPA) lowering capacity of the fixed drug combinations dorzolamide/timolol and brinzolamide/timolol. METHODS: In this cross-sectional study, one of the e …
OBJECTIVE: To determine possible differences in the intraocular pressure (IOP) and ocular pulse amplitude (OPA) lowering capacity of the fix …
Electrochemically-selective electrode for quantification of dorzolamide in bulk drug substance and dosage form.
Mora MM, Ismail NS, Zaazaa HE, Boltia SA. Mora MM, et al. BMC Chem. 2023 Aug 21;17(1):103. doi: 10.1186/s13065-023-01021-1. BMC Chem. 2023. PMID: 37605267 Free PMC article.
Three smart carbon paste electrodes were fabricated to quantify dorzolamide hydrochloride DRZ, including conventional carbon paste I, modified carbon paste embedding Silica II, and modified carbon paste embedding beta-cyclodextrin III. This study is based on the insertion …
Three smart carbon paste electrodes were fabricated to quantify dorzolamide hydrochloride DRZ, including conventional carbon paste I, …
Developing a framework regarding a complex risk based methodology in the evaluation of hazards associated with medicinal products sourced via the internet.
Vida RG, Merczel S, Jáhn E, Fittler A. Vida RG, et al. Saudi Pharm J. 2020 Dec;28(12):1733-1742. doi: 10.1016/j.jsps.2020.10.018. Epub 2020 Nov 6. Saudi Pharm J. 2020. PMID: 33424264 Free PMC article.
The probability of procuring the product from the internet was also assessed based on the number of relevant links within the first twenty search engine results and the cost of the products. With the application of the tool a dorzolamide & timolol combination ey …
The probability of procuring the product from the internet was also assessed based on the number of relevant links within the first twenty s …
[Azarga, a new and useful fixed combination in glaucoma treatment].
Călugăru M, Călugăru D. Călugăru M, et al. Oftalmologia. 2011;55(3):38-46. Oftalmologia. 2011. PMID: 22428291 Review. Romanian.
Azarga is a new fixed combination product that consists of the carbonic anhydrase inhibitor brinzolamide 1% and the betablocker timolol 0,5%. Its efficacy in lowering intraocular pressure is similar to that of Cosopt, a fixed combination that combines another carbonic anhy …
Azarga is a new fixed combination product that consists of the carbonic anhydrase inhibitor brinzolamide 1% and the betablocker timolol …
Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists.
Sharif NA, Millar JC, Zode G, Ota T. Sharif NA, et al. Int J Mol Sci. 2024 Mar 15;25(6):3328. doi: 10.3390/ijms25063328. Int J Mol Sci. 2024. PMID: 38542305 Free PMC article.
A literature survey indicated that few previously evaluated compounds (e.g., latanoprost, timolol, pilocarpine, brimonidine, dorzolamide, cromakalim analog (CKLP1), losartan, tissue plasminogen activator, trans-resveratrol, sodium 4-phenyl acetic acid, etc.) in vari …
A literature survey indicated that few previously evaluated compounds (e.g., latanoprost, timolol, pilocarpine, brimonidine, dorzo …
Water-drinking test in patients with primary open-angle glaucoma while treated with different topical medications.
Vetrugno M, Sisto D, Trabucco T, Balducci F, Delle Noci N, Sborgia C. Vetrugno M, et al. J Ocul Pharmacol Ther. 2005 Jun;21(3):250-7. doi: 10.1089/jop.2005.21.250. J Ocul Pharmacol Ther. 2005. PMID: 15969643
METHODS: A total of 280 POAG patients were enrolled, 40 patients per group for each of the tested medications (timolol, dorzolamide, brinzolamide, travoprost,latanoprost, bimatoprost, and brimonidine). ...The main outcomes measured were mean IOP peak, mean IOP perce …
METHODS: A total of 280 POAG patients were enrolled, 40 patients per group for each of the tested medications (timolol, dorzolamid …
[The role of Cosopt in glaucoma treatment].
Călugăru D, Călugăru M. Călugăru D, et al. Oftalmologia. 2008;52(4):15-25. Oftalmologia. 2008. PMID: 19354158 Review. Romanian.
The fixed combination of dorzolamide and timolol (Cosopt) represents a high effective therapy and is generally well tolerated. ...
The fixed combination of dorzolamide and timolol (Cosopt) represents a high effective therapy and is generally well tolerated. …
13 results